midazolam has been researched along with Cancer of Skin in 2 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Midazolam is an efficacious short-acting benzodiazepine with an excellent safety record." | 2.76 | The use of oral midazolam for perioperative anxiolysis of healthy patients undergoing Mohs surgery: conclusions from randomized controlled and prospective studies. ( Hoverson Schott, A; Killian, JM; Otley, CC; Phillips, PK; Ravitskiy, L; Roenigk, RK; Weaver, AL, 2011) |
| "Hemangioma was disclosed immediately after birth in 30 patients (78%)." | 1.35 | [Intralesional corticosteroid therapy in infantile hemangiomas]. ( Gawrych, E; Juszkiewicz, P; Rajewska, J; Walecka, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gawrych, E | 1 |
| Walecka, A | 1 |
| Rajewska, J | 1 |
| Juszkiewicz, P | 1 |
| Ravitskiy, L | 1 |
| Phillips, PK | 1 |
| Roenigk, RK | 1 |
| Weaver, AL | 1 |
| Killian, JM | 1 |
| Hoverson Schott, A | 1 |
| Otley, CC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled and Prospective Studies of Safety and Efficacy of Oral Midazolam for Perioperative Anxiolysis of Patients Undergoing Mohs Micrographic Surgery.[NCT00578214] | 75 participants (Actual) | Interventional | 2007-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00578214)
Timeframe: 30 minutes after drug administration
| Intervention | heart beats per minute (Mean) |
|---|---|
| Randomized Midazolam | 61.7 |
| Placebo | 64.3 |
| Prospective Midazolam | 72.1 |
(NCT00578214)
Timeframe: 60 minutes after drug administration
| Intervention | heart beats per minute (Mean) |
|---|---|
| Randomized Midazolam | 60.3 |
| Placebo | 61.4 |
| Prospective Midazolam | 69.6 |
A 10-point visual analog scale (VAS) was used to measure alertness. The patients marked on the scale their feeling of alertness. The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake). (NCT00578214)
Timeframe: Baseline (prior to drug administration)
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Midazolam | 0.2 |
| Placebo | 0.2 |
| Prospective Midazolam | 0.2 |
A 10-point visual analog scale (VAS) was used to measure anxiety. The patients marked on the scale their feeling of anxiety. The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety). (NCT00578214)
Timeframe: Baseline (prior to drug administration)
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Midazolam | 1.3 |
| Placebo | 1.4 |
| Prospective Midazolam | 3.4 |
Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test. The scores can range from 0 (low cognitive function) to 30 (high cognitive function). (NCT00578214)
Timeframe: 120 minutes after drug administration
| Intervention | units on a scale (Mean) |
|---|---|
| Randomized Midazolam | 26.0 |
| Placebo | 29.2 |
| Prospective Midazolam | 27.5 |
Pulse oximetry measures the oxygenation of a patient's hemoglobin. A sensor is placed on the patient's finger. Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector. The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance. The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules). A healthy young person will probably have an oxygen saturation of 95-99%. (NCT00578214)
Timeframe: 30 minutes after drug administration
| Intervention | percentage of oxygenation (Mean) |
|---|---|
| Randomized Midazolam | 94.5 |
| Placebo | 95.6 |
| Prospective Midazolam | 95.6 |
Pulse oximetry measures the oxygenation of a patient's hemoglobin. A sensor is placed on the patient's finger. Light at red and infrared wavelengths is passed sequentially through the patient to a photodetector. The changing absorbance at each of the two wavelengths is measured, allowing determination of the absorbance. The color of the blood provides a measure of oxygenation (the percentage of hemoglobin molecules bound with oxygen molecules). A healthy young person will probably have an oxygen saturation of 95-99%. (NCT00578214)
Timeframe: 60 minutes after drug administration
| Intervention | percentage of oxygenation (Mean) |
|---|---|
| Randomized Midazolam | 94.5 |
| Placebo | 96.4 |
| Prospective Midazolam | 95.5 |
(NCT00578214)
Timeframe: 30 minutes after drug administration
| Intervention | breaths per minute (Mean) |
|---|---|
| Randomized Midazolam | 19.4 |
| Placebo | 16.1 |
| Prospective Midazolam | 16.2 |
(NCT00578214)
Timeframe: 60 minutes after drug administration
| Intervention | breaths per minute (Mean) |
|---|---|
| Randomized Midazolam | 20.6 |
| Placebo | 16.3 |
| Prospective Midazolam | 16.8 |
(NCT00578214)
Timeframe: 30 minutes after drug administration
| Intervention | mm Hg (Mean) | |
|---|---|---|
| 30 min Systolic Blood Pressure | 30 min Diastolic Blood Pressure | |
| Placebo | 125.9 | 68.4 |
| Prospective Midazolam | 118.5 | 63.2 |
| Randomized Midazolam | 121.4 | 67.1 |
(NCT00578214)
Timeframe: 60 minutes after drug administration
| Intervention | mm Hg (Mean) | |
|---|---|---|
| 60 min systolic blood pressure | 60 min diastolic blood pressure | |
| Placebo | 131.9 | 69.5 |
| Prospective Midazolam | 113.5 | 61.5 |
| Randomized Midazolam | 120.1 | 65.3 |
A 10-point visual analog scale (VAS) was used to measure alertness. The patients marked on the scale their feeling of alertness. The lowest value possible was 0 (awake) and the highest value possible was 10 (barely awake). (NCT00578214)
Timeframe: 60 and 120 minutes after drug administration
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 60 min patient alertness | 120 min patient alertness | |
| Placebo | 0.7 | 0.5 |
| Prospective Midazolam | 5.1 | 3.4 |
| Randomized Midazolam | 3.7 | 2.1 |
A 10-point visual analog scale (VAS) was used to measure anxiety. The patients marked on the scale their feeling of anxiety. The lowest value possible was 0 (no anxiety) and the highest value possible was 10 (highest possible anxiety). (NCT00578214)
Timeframe: 60 and 120 minutes after drug administration
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 60 min patient anxiety | 120 min patient anxiety | |
| Placebo | 0.8 | 0.4 |
| Prospective Midazolam | 1.0 | 0.8 |
| Randomized Midazolam | 0.1 | 0.2 |
Cognitive function was measured by the Mini-Mental State Examination (MMSE), a brief 30 point questionnaire test. The scores can range from 0 (low cognitive function) to 30 (high cognitive function). (NCT00578214)
Timeframe: baseline (prior to drug administration) and 60 minutes after drug administration
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline Cognitive Function | 60 min Cognitive Function | |
| Placebo | 29.3 | 29.4 |
| Prospective Midazolam | 29.2 | 24.3 |
| Randomized Midazolam | 28.9 | 22.9 |
1 trial available for midazolam and Cancer of Skin
| Article | Year |
|---|---|
The use of oral midazolam for perioperative anxiolysis of healthy patients undergoing Mohs surgery: conclusions from randomized controlled and prospective studies.
Topics: Administration, Oral; Aged; Ambulatory Surgical Procedures; Anti-Anxiety Agents; Blood Pressure; Fem | 2011 |
1 other study available for midazolam and Cancer of Skin
| Article | Year |
|---|---|
[Intralesional corticosteroid therapy in infantile hemangiomas].
Topics: Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Drug Administration Schedule; Female; | 2009 |